The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and Roche Molecular Systems Inc have entered into a three-year collaboration to find out if they can predict a woman’s risk for developing cervical cancer.
The US Food and Drug Administration has awarded $2.9 million to support six research projects aimed at helping with the diagnosis, treatment and prevention of tuberculosis. The awards were issued under the agency’s Critical Path Initiative.
Novartis International AG said it is stopping work on albinterferon alfa-2b for hepatitis C and Mycograb (efungumab) for fungal infections in order to focus on more promising products. It will take a charge of $590 million in the third quarter.
A study of life-science start-ups in Britain over the five years to 2009 shows that investment per start-up in some regions is too small to ensure that the companies can be sustainable.
Researchers from the Wellcome Trust Sanger Institute in the UK and Illumina Inc of the US have mapped the genome of the Tasmanian devil, a mammal that is confronted with extinction because of infection with a transmissible facial cancer.
Oxford Nanopore Technologies Ltd has strengthened its ties with Oxford University in the UK in order to explore new applications for its sequencing technology to the field of protein sensing.
Investigators working for a Wellcome Trust Sanger Institute-funded study have found that patients with a particular DNA variant may experience a build-up of glutamate in nerve cell junctions of the brain, a process that is thought to lead to migraine attacks.
Cancer Research Technology of the UK has signed an agreement with Bayer Schering Pharma AG to evaluate new leptin antagonist peptides as potential treatments for gynaecological diseases, including cancer.
Two new approaches for treating Alzheimer’s disease have recently been disclosed. In separate announcements, a privately-owned company in Canada and researchers in Germany have put forward different approaches for disease-modifying therapies.
A new preclinical antibiotic that is being developed by GlaxoSmithKline Plc has been shown in an image fighting bacteria that are resistant to conventional antibiotics.